Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Hold” by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned an average rating of “Hold” from the ten brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $6.7143.

NMRA has been the subject of a number of research analyst reports. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $4.00 to $7.00 in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Leerink Partners initiated coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a research report on Monday, January 5th.

Insider Buying and Selling at Neumora Therapeutics

In related news, insider Paul L. Berns sold 9,819 shares of Neumora Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider directly owned 7,395,185 shares in the company, valued at $25,957,099.35. The trade was a 0.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders sold 23,387 shares of company stock worth $82,647. Company insiders own 26.80% of the company’s stock.

Institutional Investors Weigh In On Neumora Therapeutics

Hedge funds have recently modified their holdings of the stock. Siren L.L.C. boosted its position in shares of Neumora Therapeutics by 44.3% in the 4th quarter. Siren L.L.C. now owns 6,288,783 shares of the company’s stock valued at $11,257,000 after purchasing an additional 1,930,500 shares during the period. Millennium Management LLC lifted its stake in Neumora Therapeutics by 80.1% during the fourth quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock valued at $6,474,000 after buying an additional 1,608,266 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Neumora Therapeutics by 24.2% during the fourth quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock valued at $2,588,000 after buying an additional 281,926 shares in the last quarter. Ikarian Capital LLC boosted its holdings in shares of Neumora Therapeutics by 10,128.9% in the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock worth $2,288,000 after buying an additional 1,265,910 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Neumora Therapeutics by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 1,003,746 shares of the company’s stock worth $1,797,000 after buying an additional 34,818 shares during the period. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Price Performance

NASDAQ:NMRA opened at $3.22 on Tuesday. The business’s 50-day moving average price is $2.53 and its 200 day moving average price is $2.21. The firm has a market cap of $538.03 million, a P/E ratio of -2.19 and a beta of 2.46. Neumora Therapeutics has a 52-week low of $0.61 and a 52-week high of $3.65. The company has a quick ratio of 6.85, a current ratio of 6.85 and a debt-to-equity ratio of 0.15.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.